Clinical trials: Thrombocytopaenia
Antiphospholipid Syndrome, Thrombocytopenia
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
To evaluate the safety and efficacy of zanubrutinib in the treatment of antiphospholipid syndrome with secondary thrombocytopenia in 10 patients.
- Conditions
- Antiphospholipid Syndrome, Thrombocytopenia, Treatment
- Trial name
- NCT05199909
- Testing
- zanubrutinib
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Myelodysplastic Syndromes (MDS), Acute Myeloid Leukaemia (AML)
A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia
Myelodysplastic Syndrome (MDS) is a disease of the bone marrow characterized by anemia,neutropenia, and thrombocytopenia (low red blood cell, white blood cell, and platelet counts).
- Trial name
- Aza-E (NCT01488565)
- Testing
- Azacitidine and eltrombopag
- Where
- 2 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Dengue Fever, Papaya Leaf Extract
To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia
The goal of this clinical trial is to evaluate whether Carica papaya leaf extract (CPLE) can improve platelet counts in children aged 2 to 12 years diagnosed with dengue fever and thrombocytopenia.
- Conditions
- Dengue Fever, Papaya Leaf Extract, Pediatric Patients
- Trial name
- papaya leaf (NCT07172100)
- Testing
- Carica Papaya Leaf Extract Group, standard treatment
- Where
- Pakistan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ziauddin Hospital
Immune Thrombocytopenia
A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics
This study use a single-center, randomized, open, three-cycle, self-control trial design. It is planning to enroll 15 healthy adult male subjects.
- Trial name
- NCT03603132
- Testing
- Hetrombopag Olamine
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Immune Thrombocytopenia, Autoantibodies
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance…
- Conditions
- Immune Thrombocytopenia, Autoantibodies, Evan Syndrome, Connective Tissue Diseases
- Trial name
- NCT04993885
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hemangioma, Kaposiform Hemangioendothelioma
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
to evaluate the safety and efficacy of Low-dose sirolimus in Kaposiform Hemangioendothelioma in Chinese children by a prospective, randomized open trial.
- Trial name
- NCT04077515
- Testing
- Sirolimus(0.8mg/m2), Sirolimus(0.7mg/m2)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Children's Hospital of Fudan University
Thrombocytopenia
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
- Trial name
- NCT01355289
- Testing
- Avatrombopag, Pegylated interferon (PEG-IFN), Telaprevir
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eisai Inc.
Sepsis
A Multicenter Clinical Study of Romiplostim N01 in the Treatment of Sepsis-related Thrombocytopenia
This study intends to randomly divide the SAT patients admitted to the ICU into the ropivacaine N01 treatment group and the recombinant human thrombopoietin control group.
- Trial name
- ITJ(QN)2510 (NCT07595133)
- Testing
- Administer Romiplostim treatment., Administer recombinant human thrombopoietin therapy
- Volunteers
- 280 people
- Sponsor
- Shanghai 10th People's Hospital
Thrombocytopenia, Splenectomy
Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients
Evaluation of immune status before and after splenectomy in immune thrombocytopenia patients.
- Trial name
- NCT03998059
- Testing
- splenectomy
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Fetal and Neonatal Alloimmune Thrombocytopenia
Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
A prospective, non-interventional, natural history study to assess the occurrence of higher FNAIT risk across a broad population of different racial and ethnic characteristics and the occurrence of HPA-1a alloimmunization in…
- Trial name
- NCT05345561
- Testing
- Clinical data collection
- Where
- 28 sites in United States, Canada and 5 more
- Volunteers
- 14,390 people, healthy volunteers welcome
- Sponsor
- Rallybio
Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenic Purpura
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
This study involves the collection of blood samples from patients with immune thrombocytopenic purpura (ITP) to evaluate the relationship between platelet counts, blood levels of a hormone called thrombopoietin that controls…
- Trial name
- NCT00005570
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Primary Immune Thrombocytopenia (ITP)
Immunomodulation With Eltrombopag in ITP
The study aims to investigate immunomodulatory effects of eltrombopag combined with dexamethasone in young and midlife adult patients with newly diagnosed primary Immune thrombocytopenia (ITP).
- Trial name
- iROM2 (NCT04812483)
- Testing
- Eltrombopag (Revolade®), standard therapy (without eltrombopag): HD-DXM
- Where
- 6 sites in Switzerland
- Volunteers
- 2 people
- Sponsor
- University Children's Hospital Basel
Immune Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia
Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.
In France, a national prospective cohort for monitoring children and adolescents with autoimmune cytopenia OBS'CEREVANCE is in place since 2004. It is coordinated in Bordeaux by the Center's team.
- Conditions
- Immune Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, Evan Syndrome, Immunotherapy
- Trial name
- VIGICAIRE (NCT04057703)
- Volunteers
- 454 people
- Sponsor
- University Hospital, Bordeaux
Bone Marrow Diseases, Lymphoma
Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia
This is a prospective observational clinical study to characterise abnormalities of thromboelastography (TEG) parameters in patients with chemotherapy-induced thrombocytopenia.
- Trial name
- NCT01928017
- Where
- Norway
- Volunteers
- 13 people
- Sponsor
- University of Bergen
CTIT-Chemotherapy Induced Thrombocytopenia, Breast Cancer
Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study
The title of this study is: A two-cohort, single-arm, exploratory Phase II clinical study on the primary/secondary prevention ADC drug of heltrombopag for thrombocytopenia caused by breast cancer.
- Trial name
- NCT07243418
- Testing
- herombopag olamine tablets
- Volunteers
- 72 people
- Sponsor
- Fujian Cancer Hospital
Hematological Patients, Bleeding
Administration of Fibrinogen Concentrate for Refractory Bleeding
Platelet transfusions are widely employed to prevent or treat bleeding episodes in patients with thrombocytopenia. Patients with bone marrow failure secondary to haematological malignancy and chemotherapy frequently receive…
- Conditions
- Hematological Patients, Bleeding, Platelet Refractoriness
- Trial name
- FORMAT (NCT05091684)
- Testing
- Fibrinogen Concentrate Human
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Immune Thrombocytopenia
Biologic Characterization of Patients With ITP
This is a no-profit, multicenter, biological, non-pharmacologic study aimed to characterize from a biological point of view previously untreated primary ITP patients.
- Trial name
- NCT05694325
- Testing
- peripheral blood and bone marrow withdrawal
- Where
- 5 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Thrombocytopenia Associated With Liver Disease
Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag to treat adults with thrombocytopenia associated with liver disease.
- Trial name
- NCT01976104
- Testing
- avatrombopag (lower baseline platelet count), avatrombopag (higher baseline platelet count)
- Where
- 120 sites in United States, Argentina and 15 more
- Volunteers
- 204 people
- Sponsor
- Eisai Inc.
Chronic Lymphocytic Leukemia, Thrombocytopenia
Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)
The aim of this study is to find the appropriate dose of eltrombopag in thrombocytopenic CLL patients, that shortens the duration of the thrombocytopenia and achieves platelet count of ≥ 100/nl prior to the start of chemotherapy…
- Trial name
- NCT01397149
- Testing
- Eltrombopag
- Where
- 10 sites in Austria, Germany
- Volunteers
- 4 people
- Sponsor
- University of Ulm
Thrombotic Microangiopathies, Hematologic Diseases
A Safety and Efficacy Study of NAC in Patients With TA-TMA
HSCT associated thrombotic microangiopathy(TA-TMA) is a heterogeneous, fatal disorder seen within 100 days post-transplant and presents with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement…
- Trial name
- NCT03252925
- Testing
- N-Acetylcysteine
- Where
- China
- Volunteers
- 170 people
- Sponsor
- The First Affiliated Hospital of Soochow University